Related Experiment Video
Updated: Mar 27, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
13.0K
Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis
Patricia Kirschner1, Franz F Konen2, Franziska Axhausen3
1Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Moorenstraße 5, Düsseldorf 40225, Germany.
Therapeutic Advances in Neurological Disorders
|March 26, 2026
Summary
B-cell depleting therapies (BCDT) for multiple sclerosis (MS) rarely cause new or worsening psoriasis. While typically manageable, severe cases may require adjusting MS treatment, highlighting a need for further research into MS and psoriasis treatment interactions.
Area of Science:
- Immunology
- Neurology
- Dermatology
Background:
- B-cell depleting therapies (BCDT) are effective for multiple sclerosis (MS).
- Concerns exist regarding new-onset or worsening psoriasis with BCDT.
- This study investigates the relationship between BCDT and psoriasis in MS patients.
Purpose of the Study:
- To analyze clinical characteristics of MS patients developing psoriasis during BCDT.
- To examine treatment courses and outcomes for MS patients with psoriasis under BCDT.
- To understand the frequency and management of psoriasis exacerbations during BCDT.
Main Methods:
- Retrospective, multicenter analysis of 3228 MS patients treated with BCDT (2020-2024).
- Screening for new-onset or exacerbated psoriasis.
- Analysis of clinical data including Expanded Disability Status Scale and Psoriasis Area and Severity Index scores.
Main Results:
- 17 out of 3228 MS patients developed new-onset (7) or worsening (10) psoriasis.
- Median time to onset/worsening was 13 months under BCDT.
- Topical therapies were effective in most cases; four patients required MS treatment changes or specific immunotherapies.
Conclusions:
- Psoriasis onset or worsening during BCDT is a rare event in MS patients.
- Most cases are manageable with standard treatments, but severe instances may need BCDT adjustment.
- Further research is needed to explore the immunological interplay between MS and psoriasis treatments.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
732
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
732
01:22iPS Cell Differentiation
3.3K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.3K
01:29Autoimmune Disorders
2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
616
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
616